Login to Your Account



Cephalon Rejects Valeant's Hostile $5.7B Takeover Bid

By BioWorld Today Staff Reports


Wednesday, April 6, 2011
It took Cephalon Inc. less than a week to decide that Valeant Pharmaceutical International Inc.'s unsolicited offer to buy the biotech was undervalued.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription